How to improve R&D productivity: the pharmaceutical industry's grand challenge

Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes

Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525 · see citing works

Innovation in the pharmaceutical industry: New estimates of R&D costs

DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · see citing works

The present and future role of microfluidics in biomedical research

Sackmann, E. K., Fulton, A. L., & Beebe, D. J. (2014) · Nature · doi:10.1038/nature13118 · Cited by 2,995 · see citing works

Diagnosing the decline in pharmaceutical R&D efficiency

Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · see citing works

How were new medicines discovered?

Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812 · see citing works

Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures

Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744 · see citing works

Deep learning enables rapid identification of potent DDR1 kinase inhibitors

Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573 · see citing works

Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018

Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531 · see citing works

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393 · see citing works

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,347 · see citing works

Organs-on-chips at the frontiers of drug discovery

Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185 · see citing works

Advances in organ-on-a-chip engineering

Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017 · see citing works

Organs-on-chips: into the next decade

Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029 · see citing works

The productivity crisis in pharmaceutical R&D

Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918 · see citing works

Rethinking drug design in the artificial intelligence era

Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., Fisher, J., Jansen, J. M., Duca, J. S., Rush, T. S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0050-3 · Cited by 894 · see citing works

Trends in the exploitation of novel drug targets

Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853 · see citing works

Three-Dimensional Cell Cultures in Drug Discovery and Development

Fang, Y., & Eglen, R. M. (2017) · SLAS Discovery · doi:10.1177/1087057117696795 · Cited by 849 · see citing works

Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835 · see citing works

Validating therapeutic targets through human genetics

Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712 · see citing works

Role of computer-aided drug design in modern drug discovery

Macalino, S. J. Y., Gosu, V., Hong, S., & Choi, S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0640-5 · Cited by 762 · see citing works

Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval

King, E. A., Davis, J. W., & Degner, J. F. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008489 · Cited by 649 · see citing works

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692 · see citing works

Deep learning for molecular design—a review of the state of the art

Elton, D. C., Boukouvalas, Z., Fuge, M. D., & Chung, P. W. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00039a · Cited by 683 · see citing works

Genetics of coronary artery disease: discovery, biology and clinical translation

Khera, A. V., & Kathiresan, S. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.160 · Cited by 659 · see citing works

DNA-encoded chemistry: enabling the deeper sampling of chemical space

Goodnow, R. A., Dumelin, C. E., & Keefe, A. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.213 · Cited by 621 · see citing works

Exploiting machine learning for end-to-end drug discovery and development

Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., Hickey, A. J., & Clark, A. M. (2019) · Nature Materials · doi:10.1038/s41563-019-0338-z · Cited by 578 · see citing works

Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators

Bodenmiller, B., Zunder, E. R., Finck, R., Chen, T. J., Savig, E. S., Bruggner, R. V., Simonds, E. F., Bendall, S. C., Sachs, K., Krutzik, P. O., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2317 · Cited by 546 · see citing works

Screening out irrelevant cell-based models of disease

Horvath, P., Aulner, N., Bickle, M., Davies, A. M., Nery, E. D., Ebner, D., Montoya, M. C., Östling, P., Pietiäinen, V., Price, L. S., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.175 · Cited by 525 · see citing works

Phenotypic screening in cancer drug discovery — past, present and future

Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507 · see citing works

The discovery of first-in-class drugs: origins and evolution

Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514 · see citing works

Modulators of Protein–Protein Interactions

Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497 · see citing works

Drug discovery in pharmaceutical industry: productivity challenges and trends

Khanna, I. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.007 · Cited by 479 · see citing works

Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet

Bender, A., & Cortés-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.009 · Cited by 405 · see citing works

3D microtumors in vitro supported by perfused vascular networks

Sobrino, A., Phan, D. T. T., Datta, R., Wang, X., Hachey, S. J., Romero-López, M., Gratton, E., Lee, A. P., George, S. C., & Hughes, C. C. W. (2016) · Scientific Reports · doi:10.1038/srep31589 · Cited by 387 · see citing works

Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift

Golde, T. E., Schneider, L. S., & Koo, E. H. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.002 · Cited by 382 · see citing works

Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology

Ewart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00209-1 · Cited by 337 · see citing works

Drug repurposing in cancer

Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329 · see citing works

Utilizing graph machine learning within drug discovery and development

Gaudelet, T., Day, B., Jamasb, A. R., Soman, J., Regep, C., Liu, G., Hayter, J. B. R., Vickers, R., Roberts, C., Tang, J., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab159 · Cited by 313 · see citing works

The future of molecular dynamics simulations in drug discovery

Borhani, D. W., & Shaw, D. E. (2012) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9517-y · Cited by 313 · see citing works

Unreliability as a threat to understanding psychopathology: The cautionary tale of attentional bias.

Rodebaugh, T. L., Scullin, R. B., Langer, J. K., Dixon, D. J., Huppert, J. D., Bernstein, A., Zvielli, A., & Lenze, E. J. (2016) · Journal of Abnormal Psychology · doi:10.1037/abn0000184 · Cited by 312 · see citing works

Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning

Mason, D. M., Friedensohn, S., Weber, C. R., Jordi, C., Wagner, B., Meng, S. M., Ehling, R. A., Bonati, L., Dahinden, J., Gainza, P., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00699-9 · Cited by 308 · see citing works

Iminosugars as Therapeutic Agents: Recent Advances and Promising Trends

Nash, R. J., Kato, A., Yu, C.-Y., & Fleet, G. W. J. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.117 · Cited by 302 · see citing works

Information retrieval and text mining technologies for chemistry

Krallinger, M., Rabal, O., Lourenço, A., Oyarzabal, J., & Valencia, A. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00851 · Cited by 281 · see citing works

Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing

Marx, U. (2016) · ALTEX · doi:10.14573/altex.1603161 · Cited by 295 · see citing works

Machine Learning for Drug-Target Interaction Prediction

Chen, R., Liu, X., Jin, S., Lin, J., & Liu, J. (2018) · Molecules · doi:10.3390/molecules23092208 · Cited by 292 · see citing works

The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication

Rask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135943 · Cited by 282 · see citing works

Microfluidics for cell-based high throughput screening platforms—A review

Du, G., Fang, Q., & den Toonder, J. M. J. (2016) · Analytica Chimica Acta · doi:10.1016/j.aca.2015.11.023 · Cited by 276 · see citing works

A unified drug–target interaction prediction framework based on knowledge graph and recommendation system

Ye, Q., Hsieh, C.-Y., Yang, Z., Kang, Y., Chen, J., Cao, D., He, S., & Hou, T. (2021) · Nature Communications · doi:10.1038/s41467-021-27137-3 · Cited by 261 · see citing works

iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer’s Disease

Kondo, T., Imamura, K., Funayama, M., Tsukita, K., Miyake, M., Ohta, A., Woltjen, K., Nakagawa, M., Asada, T., Arai, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.109 · Cited by 221 · see citing works

A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia

Krystal, A. D., Pizzagalli, D. A., Smoski, M., Mathew, S. J., Nurnberger, J., Lisanby, S. H., Iosifescu, D., Murrough, J. W., Yang, H., Weiner, R. D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0806-7 · Cited by 227 · see citing works

Cardiovascular disease models: A game changing paradigm in drug discovery and screening

Savoji, H., Mohammadi, M. H., Rafatian, N., Toroghi, M. K., Wang, E. Y., Zhao, Y., Korolj, A., Ahadian, S., & Radisic, M. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.036 · Cited by 223 · see citing works

eToxPred: a machine learning-based approach to estimate the toxicity of drug candidates

Pu, L., Naderi, M., Liu, T., Wu, H.-C., Mukhopadhyay, S., & Brylinski, M. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0282-6 · Cited by 212 · see citing works

Pharmaceutical applications of cyanobacteria—A review

Vijayakumar, S., & Menakha, M. (2015) · Journal of Acute Medicine · doi:10.1016/j.jacme.2015.02.004 · Cited by 205 · see citing works

Rare diseases, orphan drugs and their regulation: questions and misconceptions

Tambuyzer, E. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3275 · Cited by 182 · see citing works

High-throughput organ-on-a-chip systems: Current status and remaining challenges

Probst, C., Schneider, S., & Loskill, P. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.02.004 · Cited by 171 · see citing works

Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery

Agarwal, P., Wang, H., Sun, M., Xu, J., Zhao, S., Liu, Z., Gooch, K. J., Zhao, Y., Lu, X., & He, X. (2017) · ACS Nano · doi:10.1021/acsnano.7b00824 · Cited by 168 · see citing works

Hepatic organoids for microfluidic drug screening

Au, S. H., Chamberlain, M. D., Mahesh, S., Sefton, M. V., & Wheeler, A. R. (2014) · Lab on a Chip · doi:10.1039/c4lc00531g · Cited by 162 · see citing works

The NIMH experimental medicine initiative

Insel, T. R. (2015) · World Psychiatry · doi:10.1002/wps.20227 · Cited by 165 · see citing works

Cardiovascular organ-on-a-chip platforms for drug discovery and development

Ribas, J., Sadeghi, H., Manbachi, A., Leijten, J., Brinegar, K., Zhang, Y. S., Ferreira, L., & Khademhosseini, A. (2016) · Applied In Vitro Toxicology · doi:10.1089/aivt.2016.0002 · Cited by 161 · see citing works

Modeling human carcinomas: Physiologically relevant 3D models to improve anti-cancer drug development

Unger, C., Kramer, N., Walzl, A., Scherzer, M., Hengstschläger, M., & Dolznig, H. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.015 · Cited by 158 · see citing works

Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data

Speich, B., von Niederhäusern, B., Schur, N., Hemkens, L. G., Fürst, T., Bhatnagar, N., Alturki, R., Agarwal, A., Kasenda, B., Pauli-Magnus, C., et al. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.12.018 · Cited by 146 · see citing works

The interaction between internal<scp>R</scp>&amp;<scp>D</scp>and different types of external knowledge sourcing: an empirical study of<scp>C</scp>hinese innovative firms

Chen, Y., Vanhaverbeke, W., & Du, J. (2016) · R&amp;D Management · doi:10.1111/radm.12162 · Cited by 144 · see citing works

Small‐molecule protein–protein interaction inhibitors: Therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations

Buchwald, P. (2010) · IUBMB Life · doi:10.1002/iub.383 · Cited by 133 · see citing works

Exploration of databases and methods supporting drug repurposing: a comprehensive survey

Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa003 · Cited by 131 · see citing works

Machine learning and molecular descriptors enable rational solvent selection in asymmetric catalysis

Amar, Y., Schweidtmann, A. M., Deutsch, P., Cao, L., & Lapkin, A. (2019) · Chemical Science · doi:10.1039/c9sc01844a · Cited by 132 · see citing works

Chemoproteomics and Chemical Probes for Target Discovery

Drewes, G., & Knapp, S. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.06.008 · Cited by 132 · see citing works

Phase II Trials in Drug Development and Adaptive Trial Design

Van Norman, G. A. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.005 · Cited by 133 · see citing works

Drug design on quantum computers

(2024) · doi:10.1038/s41567-024-02411-5 · Cited by 132 · see citing works

Development of spirulina for the manufacture and oral delivery of protein therapeutics

Jester, B. W., Zhao, H., Gewe, M., Adame, T., Perruzza, L., Bolick, D. T., Agosti, J., Khuong, N., Kuestner, R., Gamble, C., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01249-7 · Cited by 130 · see citing works

Human stomach-on-a-chip with luminal flow and peristaltic-like motility

Lee, K. K., McCauley, H. A., Broda, T. R., Kofron, M. J., Wells, J. M., & Hong, C. I. (2018) · Lab on a Chip · doi:10.1039/c8lc00910d · Cited by 129 · see citing works

More multiarm randomised trials of superiority are needed

Parmar, M. K. B., Carpenter, J., & Sydes, M. R. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61122-3 · Cited by 127 · see citing works

Toward developmental models of psychiatric disorders in zebrafish

Norton, W. H. J. (2013) · Frontiers in Neural Circuits · doi:10.3389/fncir.2013.00079 · Cited by 127 · see citing works

Novel Methods and Technologies for 21st-Century Clinical Trials: A Review

Dorsey, E. R., Venuto, C., Venkataraman, V., Harris, D. A., & Kieburtz, K. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4524 · Cited by 118 · see citing works

Unraveling structural mechanisms of allosteric drug action

Nussinov, R., & Tsai, C.-J. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.03.006 · Cited by 119 · see citing works

Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets

Clark, A. M., Dole, K., Coulon-Spektor, A., McNutt, A., Grass, G., Freundlich, J. S., Reynolds, R. C., & Ekins, S. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00143 · Cited by 114 · see citing works

Approaching the in vitro clinical trial: engineering organs on chips

Capulli, A. K., Tian, K., Mehandru, N., Bukhta, A., Choudhury, S. F., Suchyta, M., & Parker, K. K. (2014) · Lab on a Chip · doi:10.1039/c4lc00276h · Cited by 111 · see citing works

Drug discovery and development for rare genetic disorders

Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107 · see citing works

Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial

Javitt, D. C., Carter, C. S., Krystal, J. H., Kantrowitz, J. T., Girgis, R. R., Kegeles, L. S., Ragland, J. D., Maddock, R. J., Lesh, T. A., Tanase, C., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3572 · Cited by 100 · see citing works

CPT: Pharmacometrics and Systems Pharmacology

van der Graaf, P. H. (2012) · CPT: Pharmacometrics &amp; Systems Pharmacology · doi:10.1038/psp.2012.8 · Cited by 100 · see citing works

The design and development of covalent protein-protein interaction inhibitors for cancer treatment

Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98 · see citing works

3d organ-on-a-chip: the convergence of microphysiological systems and organoids

Baptista, L. S., Porrini, C., Kronemberger, G. S., Kelly, D. J., & Perrault, C. M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1043117 · Cited by 90 · see citing works

Privileged Electrophile Sensors: A Resource for Covalent Drug Development

Long, M. J. C., & Aye, Y. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.023 · Cited by 81 · see citing works

Repurposing quinacrine for treatment-refractory cancer

Oien, D. B., Pathoulas, C. L., Ray, U., Thirusangu, P., Kalogera, E., & Shridhar, V. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.021 · Cited by 87 · see citing works

Benchmarking data sets for the evaluation of virtual ligand screening methods: review and perspectives.

Lagarde, N., Zagury, J.-F., & Montes, M. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00090 · Cited by 85 · see citing works

Antidepressant Augmentation Using the<i>N</i>-Methyl-<scp>d</scp>-Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled Trial

Smith, E. G., Deligiannidis, K. M., Ulbricht, C. M., Landolin, C. S., Patel, J. K., & Rothschild, A. J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08252 · Cited by 82 · see citing works

The current landscape of 3D in vitro tumor models: what cancer hallmarks are accessible for drug discovery?

Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80 · see citing works

Nanoparticles Penetrate into the Multicellular Spheroid-on-Chip: Effect of Surface Charge, Protein Corona, and Exterior Flow

Huang, K., Boerhan, R., Liu, C., & Jiang, G. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00726 · Cited by 74 · see citing works

Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients

Abdallah, C. G., Dutta, A., Averill, C. L., McKie, S., Akiki, T. J., Averill, L. A., & William Deakin, J. F. (2018) · Chronic Stress · doi:10.1177/2470547018796102 · Cited by 70 · see citing works

The endless frontier? The recent increase of R&amp;D productivity in pharmaceuticals

Pammolli, F., Righetto, L., Abrignani, S., Pani, L., Pelicci, P. G., & Rabosio, E. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02313-z · Cited by 77 · see citing works

End‐to‐end continuous bioprocessing: Impact on facility design, cost of goods, and cost of development for monoclonal antibodies

Mahal, H., Branton, H., & Farid, S. S. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27774 · Cited by 71 · see citing works

Translating Oxytocin Neuroscience to the Clinic: A National Institute of Mental Health Perspective

Insel, T. R. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.002 · Cited by 56 · see citing works

Engineering EMT using 3D micro-scaffold to promote hepatic functions for drug hepatotoxicity evaluation

Wang, J., Chen, F., Liu, L., Qi, C., Wang, B., Yan, X., Huang, C., Hou, W., Zhang, M. Q., Chen, Y., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.001 · Cited by 50 · see citing works

Artificial intelligence for dementia drug discovery and trials optimization

Doherty, T., Yao, Z., Khleifat, A. A. L., Tantiangco, H., Tamburin, S., Albertyn, C., Thakur, L., Llewellyn, D. J., Oxtoby, N. P., Lourida, I., et al. (2023) · Alzheimer's &amp; Dementia · doi:10.1002/alz.13428 · Cited by 48 · see citing works

Clinical protein science in translational medicine targeting malignant melanoma

Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09468-6 · Cited by 45 · see citing works

Toward the institutionalization of quantum computing in pharmaceutical research

Zinner, M., Dahlhausen, F., Boehme, P., Ehlers, J., Bieske, L., & Fehring, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2021.10.006 · Cited by 43 · see citing works

AI's potential to accelerate drug discovery needs a reality check

(2023) · Nature · doi:10.1038/d41586-023-03172-6 · Cited by 42 · see citing works

Towards 3D in vitro models for the study of cardiovascular tissues and disease

Ryan, A. J., Brougham, C. M., Garciarena, C. D., Kerrigan, S. W., & O’Brien, F. J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.014 · Cited by 42 · see citing works

Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery

McArthur, R. A. (2017) · Neuroscience &amp; Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42 · see citing works

Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders

Lenze, E. J., Nicol, G. E., Barbour, D. L., Kannampallil, T., Wong, A. W. K., Piccirillo, J., Drysdale, A. T., Sylvester, C. M., Haddad, R., Miller, J. P., et al. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.200042 · Cited by 43 · see citing works

Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease

Gardiner, L.-J., Carrieri, A. P., Bingham, K., Macluskie, G., Bunton, D., McNeil, M., & Pyzer-Knapp, E. O. (2022) · PLOS ONE · doi:10.1371/journal.pone.0263248 · Cited by 36 · see citing works

A micropatterned human pluripotent stem cell-based ventricular cardiac anisotropic sheet for visualizing drug-induced arrhythmogenicity

Shum, A. M. Y., Che, H., Wong, A. O., Zhang, C., Wu, H., Chan, C. W. Y., Costa, K., Khine, M., Kong, C., & Li, R. A. (2017) · Advanced Materials · doi:10.1002/adma.201602448 · Cited by 37 · see citing works